Clinical Trial Update: A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating adverse events and disease activity changes with ABBV-706 versus standard of care in adults with relapsed/refractory small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• ABBV-706

Snippet

Sponsor: AbbVie | Conditions: Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING